Home > Gastroenterology > Liquid biopsy to screen for colorectal cancer recurrence has limitations

Liquid biopsy to screen for colorectal cancer recurrence has limitations


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Network Open
Reuters Health - 10/03/2022 - The Signatera circulating tumor DNA (ctDNA) assay provides "no definitive advantage" over standard imaging and carcinoembryonic antigen (CEA) tests in the surveillance of patients with resected colorectal cancer (CRC), researchers report.  The assay is used in the United States for surveillance of resected CRC "despite limited data supporting such practice," Dr. Marwan Fakih, co-director of gastrointestinal cancer program at City of Hope, in Duarte, California, and colleagues note in JAMA Network Open.  In a study of 48 patients with resected CRC, the researchers sough to determine whether serial ctDNA analysis is more sensitive an...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on